{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    42,
    43,
    44,
    45,
    46,
    51,
    52,
    53,
    56,
    58,
    62,
    67,
    68,
    69,
    70,
    71,
    72,
    73,
    74,
    91,
    92,
    93,
    94,
    111
  ],
  "modelUsed": "gemini-2.5-pro",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of study treatment"
      },
      {
        "id": "anchor_3",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_4",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P21D",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_3",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_34",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_daily_41",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_daily_71",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "daily oral administration"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P28D",
        "sourceText": "28-day cycle"
      },
      {
        "id": "rep_cycle_3",
        "type": "Cycle",
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "rep_cycle_4",
        "type": "Cycle",
        "sourceText": "Cycle 4 Day 1"
      },
      {
        "id": "rep_cycle_5",
        "type": "Cycle",
        "sourceText": "Cycle 7 Day 1"
      },
      {
        "id": "rep_cycle_6",
        "type": "Cycle",
        "sourceText": "Cycle 13 Day 1"
      },
      {
        "id": "rep_cycle_7",
        "type": "Cycle",
        "sourceText": "C7D1"
      },
      {
        "id": "rep_cycle_8",
        "type": "Cycle",
        "sourceText": "C10D1"
      },
      {
        "id": "rep_cycle_9",
        "type": "Cycle",
        "sourceText": "C13D1"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P21D",
        "sourceText": "Days 1 to 21"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P21D",
        "sourceText": "Days 1- 21"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "sourceText": "treatment phase"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "Treatment Phase"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "follow-up phase"
      },
      {
        "id": "rep_window_11",
        "type": "Continuous",
        "sourceText": "28 days after"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "1 hour before"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "2 hours after"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "10 hours before"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "6 days before"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "2 hours before"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "10 hours \nbefore"
      },
      {
        "id": "rep_window_25",
        "type": "Continuous",
        "sourceText": "7 days \nafter"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "sourceText": "blood chemistry will be performed every 3 cycles (Day 1) after approval of Amendment 3"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "Crossover"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_4"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Treatment Visit",
          "Screening",
          "Day 1",
          "Day 1 of each treatment cycle",
          "Required Assessment",
          "Survival Follow-up Visits",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'If subject discontinues treatment due to adverse events', 'path': ['EARLY_TERMINATION_VISIT', '28_DAY_SAFETY_FOLLOW_UP']}, {'condition': 'If subject discontinues treatment for reasons other than disease progression', 'path': ['EARLY_TERMINATION_VISIT', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'If subject discontinues treatment due to disease progression', 'path': ['EARLY_TERMINATION_VISIT', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'If subject permanently discontinues palbociclib/placebo', 'path': ['FULVESTRANT_MONOTHERAPY', 'FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3; RECURRING signals: 1"
      },
      {
        "activityId": "Ecg",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Adverse Event",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; RECURRING signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; SINGLE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1; EPISODE signals: 1; SINGLE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2; RECURRING signals: 2"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Recurring",
        "rationale": "WINDOW signals: 1; SINGLE signals: 1; RECURRING signals: 2"
      },
      {
        "activityId": "Tumor Assessments",
        "executionType": "Single",
        "rationale": "The protocol describes conducting tumor assessments over time, originally on a fixed schedule and later amended to 'as per local practice', indicating periodic repeats."
      },
      {
        "activityId": "Survival Follow-up",
        "executionType": "Single",
        "rationale": "The protocol specifies that survival follow-up visits will be conducted 'every 3 months'."
      },
      {
        "activityId": "Blood Chemistry",
        "executionType": "Single",
        "rationale": "The protocol states that blood chemistry will be performed 'every 3 cycles (Day 1)'."
      },
      {
        "activityId": "Adverse Event-driven Blood Chemistry",
        "executionType": "Single",
        "rationale": "Collection is conditional based on a specific trigger: 'if an adverse event occurs that mandates blood chemistry to be performed'."
      },
      {
        "activityId": "Hemoglobin A1c",
        "executionType": "Single",
        "rationale": "The protocol specifies this test will be performed 'at the time of blood chemistry', which is a recurring event."
      },
      {
        "activityId": "Ophthalmology Tests",
        "executionType": "Single",
        "rationale": "The protocol states these tests 'will continue to be collected', implying a pre-existing schedule of repeated assessments at study visits."
      },
      {
        "activityId": "Hematology Tests for Retreatment",
        "executionType": "Single",
        "rationale": "This is a conditional workflow where tests 'must meet retreatment criteria prior to administering palbociclib', representing a decision point before each treatment cycle."
      },
      {
        "activityId": "Physical Examination/Vital Signs",
        "executionType": "Single",
        "rationale": "The protocol mentions clarifying the timing for these assessments, which are standard procedures performed repeatedly at scheduled study visits."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "Crossover"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "\nProtocol Summary-Background and \nRationale/Section",
        "footnoteId": "f.",
        "sourceText": "\nProtocol Summary-Background and \nRationale/Section"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "\nProtocol Summary-Study Design/Schedule of \nActivities/Section",
        "footnoteId": "d.",
        "sourceText": "\nProtocol Summary-Study Design/Schedule of \nActivities/Section"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "The \ninvestigators will stop sending the imaging\nstudies to the central laboratory",
        "footnoteId": "a.",
        "structuredCondition": "procedure.stop(send_to_central_lab, imaging_studies)",
        "appliesToActivityIds": [
          "imaging studies"
        ],
        "sourceText": "The \ninvestigators will stop sending the imaging\nstudies to the central laboratory"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "\nProtocol Summary-Schedule of Activities: \nClarified that ophthalmology tests will continue \nto be collected",
        "footnoteId": "y.",
        "sourceText": "\nProtocol Summary-Schedule of Activities: \nClarified that ophthalmology tests will continue \nto be "
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "\nProtocol Summary-Tumor Assessment \nRequirements Flow Chart/Section",
        "footnoteId": "b.",
        "sourceText": "\nProtocol Summary-Tumor Assessment \nRequirements Flow Chart/Section"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "\nSchedule of Activities/Study design: Added \nclarification to the schedule of administration of \nfulvestrant and goserelin",
        "footnoteId": "m.",
        "sourceText": "\nSchedule of Activities/Study design: Added \nclarification to the schedule of administration of \nfu"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "Refer to STUDY PROCEDURES and \nASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the \nprotocol",
        "footnoteId": "s.",
        "sourceText": "Refer to STUDY PROCEDURES and \nASSESSMENTS sections of the protocol for detailed information on each"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "Upon approval, \nsome of the safety and efficacy assessments\nwill be reduced due to:",
        "footnoteId": "3.",
        "sourceText": "Upon approval, \nsome of the safety and efficacy assessments\nwill be reduced due to:"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "As a consequence, the \nrequirement of conducting tumor assessment at \nthe End of Treatment visit will not be \nmandatory any longer",
        "footnoteId": "3.",
        "structuredCondition": "procedure.mandatory(tumor_assessment, false) WHERE timepoint == 'End of Treatment'",
        "appliesToActivityIds": [
          "tumor assessment"
        ],
        "sourceText": "As a consequence, the \nrequirement of conducting tumor assessment at \nthe End of Treatment visit wil"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "It was also clarified that, if \nan adverse event occurs that mandates blood \nchemistry to be performed",
        "footnoteId": "3.",
        "sourceText": "It was also clarified that, if \nan adverse event occurs that mandates blood \nchemistry to be perform"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "Human Pharmacokinetic Data: \nUpdated section to add data findings to support:",
        "footnoteId": "2.",
        "sourceText": "Human Pharmacokinetic Data: \nUpdated section to add data findings to support:"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Investigator-Assessed Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "randomization_date",
          "date_of_objective_progression",
          "date_of_death"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "Until disease progression or death"
        },
        "algorithm": "Time from randomization to the first documentation of objective disease progression or death from any cause, whichever occurs first. PFS = MIN(date_of_objective_progression, date_of_death) - randomization_date.",
        "successCriteria": "Demonstrate superiority of the palbociclib + fulvestrant arm over the fulvestrant alone arm in prolonging PFS.",
        "sourceText": "To demonstrate the superiority of palbociclib in combination with fulvestrant (with or without goserelin) over fulvestrant alone (with or without goserelin) in prolonging investigator-assessed PFS in "
      },
      {
        "id": "ep_2",
        "name": "Safety Comparison",
        "endpointType": "Secondary",
        "inputs": [
          "adverse_events_data",
          "treatment_arm"
        ],
        "timeWindow": {
          "reference": "start of treatment",
          "duration": "Throughout the active treatment period"
        },
        "algorithm": "Comparison of the incidence, severity, and type of adverse events between the two treatment arms.",
        "successCriteria": "Characterize and compare the safety profile of the palbociclib combination arm versus the placebo combination arm.",
        "sourceText": "The safety between the two treatment arms will also be compared."
      },
      {
        "id": "ep_3",
        "name": "Patient Reported Outcomes (PRO) / Quality of Life (QoL)",
        "endpointType": "Secondary",
        "inputs": [
          "PRO_questionnaire_scores",
          "treatment_arm",
          "assessment_timepoint"
        ],
        "timeWindow": {
          "reference": "start of treatment",
          "duration": "Throughout the active treatment period"
        },
        "algorithm": "Comparison of global Quality of Life (QoL) scores and other health-related quality of life metrics between the two treatment arms over time.",
        "successCriteria": "Demonstrate a statistically significantly higher on-treatment global QoL in the palbociclib arm compared to the placebo arm, or maintenance of QoL.",
        "sourceText": "Patient Reported Outcomes (PRO) will be collected to evaluate health-related quality of life and health status."
      },
      {
        "id": "ep_4",
        "name": "Molecular Profiling for Sensitivity and Resistance",
        "endpointType": "Exploratory",
        "inputs": [
          "tumor_tissue_molecular_data",
          "clinical_outcome_data"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "N/A (correlative analysis)"
        },
        "algorithm": "Assess the relationship between the alteration of cell cycle pathway-related genes and proteins in tumor tissues and clinical outcomes (sensitivity and resistance) to palbociclib.",
        "successCriteria": "Identify potential biomarkers of response or resistance to palbociclib.",
        "sourceText": "The study will also include a molecular profiling component aimed at assessing the relationship between breast tumor sensitivity and resistance to palbociclib and the alteration of cell cycle pathway-"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "QTcF change from baseline",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "QTcF"
        ],
        "derivationRule": "Post-treatment QTcF value - Baseline QTcF value",
        "baselineDefinition": "Not specified",
        "baselineVisit": "Not specified",
        "analysisWindow": "Not specified",
        "imputationRule": "Not specified",
        "unit": "msec"
      },
      {
        "id": "dv_2",
        "name": "Clinically significant decrease in best-corrected visual acuity",
        "variableType": "Categorical",
        "sourceVariables": [
          "Best-corrected visual acuity"
        ],
        "derivationRule": "A decrease of 3 or more lines from the Screening visit value. If screening acuity is better than 20/20, the decrease is calculated from 20/20. This is reported as an adverse event.",
        "baselineDefinition": "Value at the Screening visit. If acuity at screening is better than 20/20, baseline is considered 20/20 for calculation.",
        "baselineVisit": "Screening",
        "analysisWindow": "All subsequent study visits",
        "imputationRule": "Not specified",
        "unit": "lines"
      },
      {
        "id": "dv_3",
        "name": "Clinically significant change in refraction power",
        "variableType": "Categorical",
        "sourceVariables": [
          "Refraction power (spherical)",
          "Refraction power (cylindrical)"
        ],
        "derivationRule": "A change (increase or decrease) of 1.25 diopters or more in spherical or cylindrical refraction power compared with the screening examination. This is reported as an adverse event.",
        "baselineDefinition": "Value at the screening examination.",
        "baselineVisit": "Screening",
        "analysisWindow": "Not specified",
        "imputationRule": "Not specified",
        "unit": "diopters"
      },
      {
        "id": "dv_4",
        "name": "Adverse Event Trigger for Intraocular Pressure (IOP)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Intraocular pressure (IOP)"
        ],
        "derivationRule": "An adverse event is reported if either of the following criteria are met: 1) IOP increase of greater than 10 mmHg above baseline, OR 2) any IOP that increases above 25 mm Hg.",
        "baselineDefinition": "Not specified for the 'increase from baseline' criterion.",
        "baselineVisit": "Not specified",
        "analysisWindow": "Not specified",
        "imputationRule": "Not specified",
        "unit": "mmHg"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Active Treatment Phasea - One Cycle = 28 days",
        "End of Treatment/Withdrawalc",
        "Post-Treatment Follow-Upd",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Active Treatment Phasea - One Cycle = 28 days",
          "trigger": "Progress to Active Treatment Phasea - One Cycle = 28 days"
        },
        {
          "fromState": "Active Treatment Phasea - One Cycle = 28 days",
          "toState": "End of Treatment/Withdrawalc",
          "trigger": "Progress to End of Treatment/Withdrawalc"
        },
        {
          "fromState": "End of Treatment/Withdrawalc",
          "toState": "Post-Treatment Follow-Upd",
          "trigger": "Progress to Post-Treatment Follow-Upd"
        },
        {
          "fromState": "Active Treatment Phasea - One Cycle = 28 days",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "End of Treatment/Withdrawalc",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Post-Treatment Follow-Upd",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "epoch_1",
        "Active Treatment Phasea - One Cycle = 28 days": "epoch_2",
        "End of Treatment/Withdrawalc": "epoch_3",
        "Post-Treatment Follow-Upd": "epoch_4",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "RECIST version",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.1,
            "unit": "g"
          }
        ],
        "sourceText": " Section 6.6.1 (Active Treatment Phase Discontinuation) – Clarified that routine safety assessments must continue if patient continues study treatment despite progression of disease.  Appendix 4 (RE"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_5",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Screening Active Treatment Phasea - One Cycle = 28 days End of"
      },
      {
        "id": "visit_8",
        "visitName": "Baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Baseline Signs/Symptomsg Xg Physical Examination/Vital Signsh"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": 1,
        "windowBefore": 2,
        "windowAfter": 2,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Active Treatment",
        "sourceText": "some of the safety and efficacy assessments will be reduced due to: 1) completion of efficacy analyses including interim and final"
      },
      {
        "id": "visit_3",
        "visitName": "End of Treatment",
        "targetDay": 1,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "the End of Treatment visit will not be mandatory any longer. "
      },
      {
        "id": "visit_4",
        "visitName": "Day 1",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "performed every 3 cycles (Day 1) after approval of Amendment 3. It was also clarified that, if an adverse event occurs that mandates blood"
      },
      {
        "id": "visit_6",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "randomization unless specified otherwise Day 1b"
      },
      {
        "id": "visit_10",
        "visitName": "end of study",
        "targetDay": 1,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "evaluated at baseline, during and at the end of study treatment. By adding these examinations the sponsor is addressing a request by the Food and Drug Administration (FDA) for the palbociclib program."
      },
      {
        "id": "visit_9",
        "visitName": "Day 14",
        "targetDay": 14,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "the pooled plasma samples on Day 14 of Cycle 1 indicated that the glucuronide conjugate of palbociclib and the lactam of palbociclib (PF-05089326) were the main metabolites present in plasma. Other me"
      },
      {
        "id": "visit_7",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 2,
        "windowAfter": 2,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Active Treatment",
        "sourceText": "Day 15 Day 1 Visit Window"
      },
      {
        "id": "visit_11",
        "visitName": "Week 8",
        "targetDay": 50,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 8,
        "sourceText": "same assessment schedule (ie, Week 8 7 days from randomization) as for all other lesions. Areas that have received palliative radiotherapy cannot be used to assess response to study treatment."
      },
      {
        "id": "visit_2",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "under observation for a follow-up period of approximately 1 year and a half. "
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Documented sensitivity to prior hormonal therapy",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Menopausal status at study entry",
          "categories": [
            "Pre-/peri-menopausal",
            "Post-menopausal"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Presence of visceral metastases",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "PD-0332991 (Palbociclib)\nA5481023 (PALOMA-3)\nFinal Protocol Amendment 3, 20 October2015\nPFIZER CONFIDENTIAL\nPage 10\nIn the present study, adverse events seen with palbociclib and fulvestrant were cons"
    }
  }
}